Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PRKACA

Gene summary for PRKACA

Gene summary.

Gene information	Species	Human
	Gene symbol	PRKACA
	Gene ID	5566
	Gene name	protein kinase cAMP-activated catalytic subunit alpha
	Gene Alias	CAFD1
	Cytomap	19p13.12
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	P17612

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
5566	PRKACA	HCC1_Meng	Human	Liver	HCC	2.82e-37	6.69e-02	0.0246
5566	PRKACA	HCC2_Meng	Human	Liver	HCC	3.10e-09	7.98e-02	0.0107
5566	PRKACA	HCC1	Human	Liver	HCC	5.42e-05	1.68e+00	0.5336
5566	PRKACA	S015	Human	Liver	HCC	4.62e-03	2.89e-01	0.2375
5566	PRKACA	S027	Human	Liver	HCC	2.94e-08	8.13e-01	0.2446
5566	PRKACA	S028	Human	Liver	HCC	1.11e-19	8.44e-01	0.2503
5566	PRKACA	S029	Human	Liver	HCC	1.04e-18	8.21e-01	0.2581
5566	PRKACA	C04	Human	Oral cavity	OSCC	6.90e-11	7.00e-01	0.2633
5566	PRKACA	C21	Human	Oral cavity	OSCC	2.55e-10	4.45e-01	0.2678
5566	PRKACA	C30	Human	Oral cavity	OSCC	5.74e-08	5.68e-01	0.3055
5566	PRKACA	C51	Human	Oral cavity	OSCC	1.57e-06	4.50e-01	0.2674
5566	PRKACA	C08	Human	Oral cavity	OSCC	4.48e-08	8.85e-02	0.1919
5566	PRKACA	SYSMH1	Human	Oral cavity	OSCC	4.20e-02	1.13e-01	0.1127
5566	PRKACA	SYSMH2	Human	Oral cavity	OSCC	2.97e-03	1.72e-01	0.2326
5566	PRKACA	SYSMH3	Human	Oral cavity	OSCC	7.69e-12	3.02e-01	0.2442
5566	PRKACA	SYSMH6	Human	Oral cavity	OSCC	2.62e-02	8.34e-02	0.1275
5566	PRKACA	male-WTA	Human	Thyroid	PTC	3.42e-37	4.23e-01	0.1037
5566	PRKACA	nodule-WTA	Human	Thyroid	goiters	1.88e-02	1.91e-01	0.0534
5566	PRKACA	PTC01	Human	Thyroid	PTC	3.52e-04	6.22e-02	0.1899
5566	PRKACA	PTC04	Human	Thyroid	PTC	3.53e-06	1.72e-01	0.1927

Page: 1 2 3

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0042176	Colorectum	AD	regulation of protein catabolic process	160/3918	391/18723	1.06e-19	7.34e-17	160
GO:1903362	Colorectum	AD	regulation of cellular protein catabolic process	109/3918	255/18723	2.14e-15	6.08e-13	109
GO:0010498	Colorectum	AD	proteasomal protein catabolic process	174/3918	490/18723	3.18e-14	7.66e-12	174
GO:1903050	Colorectum	AD	regulation of proteolysis involved in cellular protein catabolic process	92/3918	221/18723	2.04e-12	3.19e-10	92
GO:0045216	Colorectum	AD	cell-cell junction organization	80/3918	200/18723	5.57e-10	4.58e-08	80
GO:0051098	Colorectum	AD	regulation of binding	126/3918	363/18723	6.01e-10	4.88e-08	126
GO:0061136	Colorectum	AD	regulation of proteasomal protein catabolic process	75/3918	187/18723	1.65e-09	1.20e-07	75
GO:1904951	Colorectum	AD	positive regulation of establishment of protein localization	112/3918	319/18723	2.55e-09	1.80e-07	112
GO:0010506	Colorectum	AD	regulation of autophagy	111/3918	317/18723	3.57e-09	2.35e-07	111
GO:0016236	Colorectum	AD	macroautophagy	103/3918	291/18723	6.76e-09	4.15e-07	103
GO:0051222	Colorectum	AD	positive regulation of protein transport	106/3918	303/18723	8.45e-09	5.08e-07	106
GO:0034329	Colorectum	AD	cell junction assembly	136/3918	420/18723	2.02e-08	1.15e-06	136
GO:0006913	Colorectum	AD	nucleocytoplasmic transport	102/3918	301/18723	1.00e-07	4.85e-06	102
GO:0051169	Colorectum	AD	nuclear transport	102/3918	301/18723	1.00e-07	4.85e-06	102
GO:0090316	Colorectum	AD	positive regulation of intracellular protein transport	62/3918	160/18723	1.82e-07	7.79e-06	62
GO:0032388	Colorectum	AD	positive regulation of intracellular transport	74/3918	202/18723	1.83e-07	7.80e-06	74
GO:0007043	Colorectum	AD	cell-cell junction assembly	57/3918	146/18723	4.18e-07	1.61e-05	57
GO:0032386	Colorectum	AD	regulation of intracellular transport	109/3918	337/18723	5.33e-07	1.95e-05	109
GO:0033157	Colorectum	AD	regulation of intracellular protein transport	80/3918	229/18723	5.81e-07	2.09e-05	80
GO:0009743	Colorectum	AD	response to carbohydrate	86/3918	253/18723	8.43e-07	2.90e-05	86

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05012	Colorectum	AD	Parkinson disease	147/2092	266/8465	2.53e-27	8.48e-25	5.41e-25	147
hsa04714	Colorectum	AD	Thermogenesis	120/2092	232/8465	2.76e-19	1.16e-17	7.37e-18	120
hsa05020	Colorectum	AD	Prion disease	133/2092	273/8465	2.47e-18	8.29e-17	5.29e-17	133
hsa04530	Colorectum	AD	Tight junction	76/2092	169/8465	5.49e-09	9.69e-08	6.18e-08	76
hsa05110	Colorectum	AD	Vibrio cholerae infection	29/2092	50/8465	5.10e-07	7.12e-06	4.54e-06	29
hsa04919	Colorectum	AD	Thyroid hormone signaling pathway	51/2092	121/8465	1.71e-05	1.73e-04	1.10e-04	51
hsa04723	Colorectum	AD	Retrograde endocannabinoid signaling	59/2092	148/8465	2.94e-05	2.73e-04	1.74e-04	59
hsa04961	Colorectum	AD	Endocrine and other factor-regulated calcium reabsorption	24/2092	53/8465	8.49e-04	5.93e-03	3.78e-03	24
hsa04213	Colorectum	AD	Longevity regulating pathway - multiple species	27/2092	62/8465	8.72e-04	5.96e-03	3.80e-03	27
hsa04922	Colorectum	AD	Glucagon signaling pathway	41/2092	107/8465	1.18e-03	7.75e-03	4.94e-03	41
hsa05205	Colorectum	AD	Proteoglycans in cancer	70/2092	205/8465	1.37e-03	8.46e-03	5.39e-03	70
hsa05163	Colorectum	AD	Human cytomegalovirus infection	75/2092	225/8465	2.00e-03	1.10e-02	7.01e-03	75
hsa04912	Colorectum	AD	GnRH signaling pathway	35/2092	93/8465	3.69e-03	1.90e-02	1.21e-02	35
hsa04140	Colorectum	AD	Autophagy - animal	49/2092	141/8465	4.58e-03	2.20e-02	1.40e-02	49
hsa05166	Colorectum	AD	Human T-cell leukemia virus 1 infection	72/2092	222/8465	5.24e-03	2.44e-02	1.55e-02	72
hsa04962	Colorectum	AD	Vasopressin-regulated water reabsorption	19/2092	44/8465	5.48e-03	2.48e-02	1.58e-02	19
hsa04728	Colorectum	AD	Dopaminergic synapse	46/2092	132/8465	5.55e-03	2.48e-02	1.58e-02	46
hsa04211	Colorectum	AD	Longevity regulating pathway	33/2092	89/8465	6.15e-03	2.68e-02	1.71e-02	33
hsa04971	Colorectum	AD	Gastric acid secretion	29/2092	76/8465	6.25e-03	2.68e-02	1.71e-02	29
hsa04928	Colorectum	AD	Parathyroid hormone synthesis, secretion and action	38/2092	106/8465	6.60e-03	2.77e-02	1.76e-02	38

Page: 1 2 3 4 5 6 7 8 9 10 11

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PRKACA

SNV

Missense_Mutation

c.382N>C

p.Glu128Gln

p.E128Q

P17612

protein_coding

deleterious(0)

probably_damaging(0.989)

TCGA-A8-A07J-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

PRKACA

SNV

Missense_Mutation

c.656N>T

p.Ala219Val

p.A219V

P17612

protein_coding

deleterious(0)

probably_damaging(0.962)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

PRKACA

SNV

Missense_Mutation

c.248T>C

p.Leu83Pro

p.L83P

P17612

protein_coding

deleterious(0)

probably_damaging(0.925)

TCGA-E2-A15L-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

PRKACA

SNV

Missense_Mutation

c.589N>A

p.Trp197Arg

p.W197R

P17612

protein_coding

deleterious(0)

probably_damaging(0.91)

TCGA-E2-A1IU-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

PRKACA

SNV

Missense_Mutation

c.376N>A

p.Gly126Ser

p.G126S

P17612

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-GM-A2DO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

PRKACA

deletion

Frame_Shift_Del

novel

c.871delN

p.Asp291IlefsTer99

p.D291Ifs*99

P17612

protein_coding

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

PRKACA

SNV

Missense_Mutation

c.710C>T

p.Pro237Leu

p.P237L

P17612

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-C5-A7CH-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unspecific

PRKACA

SNV

Missense_Mutation

c.450G>T

p.Gln150His

p.Q150H

P17612

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

PRKACA

SNV

Missense_Mutation

c.700N>A

p.Ala234Thr

p.A234T

P17612

protein_coding

deleterious(0.04)

possibly_damaging(0.567)

TCGA-CK-5913-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

PRKACA

SNV

Missense_Mutation

c.442N>A

p.Ala148Thr

p.A148T

P17612

protein_coding

deleterious(0.02)

probably_damaging(0.951)

TCGA-AJ-A23O-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		ALISERTIB	ALISERTIB
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		TCMDC-125758	CHEMBL546797
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		CYC-116	CYC-116
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		AG-1879	CHEMBL406845
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		CENISERTIB	CENISERTIB
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		GO-6976	GO-6976
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE	inhibitor	CHEMBL494089	GSK-690693
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		PD-0166285	PD-0166285
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE	inhibitor	178102606	CHEMBL104264
5566	PRKACA	SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		FASUDIL	FASUDIL

Page: 1 2 3